Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Stephen Huberman, M.D.

Co-Author

This page shows the publications co-authored by Mark Huberman and Daniel Tenen.
Connection Strength

0.188
  1. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103.
    View in: PubMed
    Score: 0.090
  2. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53.
    View in: PubMed
    Score: 0.028
  3. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7.
    View in: PubMed
    Score: 0.025
  4. Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8105.
    View in: PubMed
    Score: 0.024
  5. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.